Center for Scientific Review; Notice of Closed Meetings, 48167-48168 [05-16214]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 157 / Tuesday, August 16, 2005 / Notices
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, National Library of Medicine,
National Center for Biotechnology
Information.
Date: October 25, 2005.
Open: 9 a.m. to 12 p.m.
Agenda: Program discussion.
Place: National Library of Medicine,
Building 38, Board Room, 2nd Floor, 8600
Rockville Pike, Bethesda, MD 20892.
Closed: 12 p.m. to 2 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Library of Medicine,
Building 38, Board Room, 2nd Floor, 8600
Rockville Pike, Bethesda, MD 20892.
Open: 2 p.m. to 5 p.m.
Agenda: Program discussion.
Place: National Library of Medicine,
Building 38, Board Room, 2nd Floor, 8600
Rockville Pike, Bethesda, MD 20892.
Contact Person: David J. Lipman, MD,
Director, Natl Ctr for Biotechnology
Information, National Library of Medicine,
Department of Health and Human Services,
Building 38A, Room 8N805, Bethesda, MD
20894, 301–435–5985,
dlipman@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
into the building by non-government
employees. Persons without a government
I.D. will need to show a photo I.D. and signin at the security desk upon entering the
building.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.879, Medical Library
Assistance, National Institutes of Health,
HHS)
Dated: August 10, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–16211 Filed 8–15–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
Recambinant DNA Advisory Committee.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
VerDate jul<14>2003
18:02 Aug 15, 2005
Jkt 205001
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: Recombinant
DNA Advisory Committee.
Date: September 21, 2005.
Time: 8 a.m. to 6 p.m.
Agenda: The committee will review
and discuss selected human gene
transfer protocols as well as related data
management activities.
Place: Bethesda Marriott, 5151 Pooks
Hill Road, Bethesda, MD 20814.
Contact Person: Laurie Lewallen,
Advisory Committee Coordinator, Office
of Biotechnology Activities, National
Institutes of Health, 6705 Rockledge
Drive, Room 750, Bethesda, MD 20892–
7985, (301) 496–9838,
lewalla@od.nih.gov.
Any interested person may file
written comments with the committee
by forwarding the statement to the
Contact Person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www4.od.nih.gov/oba/, where an agenda
and any additional information for the
meeting will be posted when available.
OMB’s ‘‘Mandatory Information
Requirements for Federal Assistance
Program Announcements’’ (45 FR
39592, June 11, 1980) requires a
statement concerning the official
government programs contained in the
Catalog of Federal Domestic Assistance.
Normally NIH lists in its
announcements the number and title of
affected individual programs for the
guidance of the public. Because the
guidance in this notice covers virtually
every NIH and Federal research program
in which DNA recombinant molecule
techniques could be used, it has been
determined not to be cost effective or in
the public interest to attempt to list
these programs. Such a list would likely
require several additional pages. In
addition, NIH could not be certain that
every Federal program would be
included as many Federal agencies, as
well as private organizations, both
national and international, have elected
to follow the NIH Guidelines. In lieu of
the individual program listing, NIH
invites readers to direct questions to the
information address above about
whether individual programs listed in
the Catalog of Federal Domestic
assistance are affected.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
48167
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: August 9, 2005.
Anthony M. Coehlo, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–16210 Filed 8–15–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (U.S.C. Appendix 2), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Protection
Against Doxorubicin-Induced
Cardiomyopathy.
Date: August 16, 2005.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone conference call).
Contact Person: Anshumali Chaudhari,
PhD, Scientific Review Administrator, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4124,
MSC 7802, Bethesda, MD 20892, (301) 435–
1210, chaudhaa@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Small
Business Grant Applications: Immunology.
Date: August 24, 2005.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\16AUN1.SGM
16AUN1
48168
Federal Register / Vol. 70, No. 157 / Tuesday, August 16, 2005 / Notices
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone conference call).
Contact Person: Stephen M. Nigida, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4212,
MSC 7812, Bethesda, MD 20892, 301–435–
1222, nigidas@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: August 10, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–16214 Filed 8–15–05; 8:45 am]
Proposed Project: 2006 National Survey
on Drug Use and Health—(OMB No.
0930–0110)—Revision
The National Survey on Drug Use and
Health (NSDUH), formerly the National
Household Survey on Drug Abuse
(NHSDA), is a survey of the civilian,
noninstitutionalized population of the
United States 12 years old and older.
The data are used to determine the
BILLING CODE 4140–01–M
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
prevalence of use of tobacco products,
alcohol, illicit substances, and illicit use
of prescription drugs. The results are
used by SAMHSA, ONDCP, Federal
government agencies, and other
organizations and researchers to
establish policy, direct program
activities, and better allocate resources.
For the 2006 NSDUH, additional
questions are being planned regarding
self-help drug treatment, use of
additional hallucinogens, prescription
drugs and over the counter medications,
respondent’s place of residence, and
alcohol consumption practices. To
maintain the respondent burden at 60
minutes per interview, a few questions
will be deleted. The remaining modular
components of the questionnaire will
remain essentially unchanged except for
minor modifications to wording.
As with all NSDUH/NHSDA surveys
conducted since 1999, the sample size
of the survey for 2006 will be sufficient
to permit prevalence estimates for each
of the fifty states and the District of
Columbia.
The total annual burden estimate is
shown below:
Number of respondents
Number of responses per
respondent
Average burden
hours per respondent
Household Screening ....................................................................................
Interview .........................................................................................................
Re-interview ...................................................................................................
Screening Verification ....................................................................................
Interview Verification ......................................................................................
Re-Interview Verification ................................................................................
182,250
67,500
3,100
5,494
10,125
1,550
1
1
1
1
1
1
.083
1.0
1.0
.067
.067
.067
15,127
67,500
3,100
368
678
104
TOTAL ....................................................................................................
182,250
........................
..........................
86,877
Activity
Written comments and
recommendations concerning the
proposed information collection should
be sent by September 15, 2005 to:
SAMHSA Desk Officer, Human
Resources and Housing Branch, Office
of Management and Budget, New
Executive Office Building, Room 10235,
Washington, DC 20503; due to potential
delays in OMB’s receipt and processing
of mail sent through the U.S. Postal
Service, respondents are encouraged to
submit comments by fax to: 202–395–
6974.
Dated: August 10, 2005.
Anna Marsh,
Executive Officer, SAMHSA.
[FR Doc. 05–16177 Filed 8–15–05; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
BILLING CODE 4162–20–P
VerDate jul<14>2003
18:02 Aug 15, 2005
Jkt 205001
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
Total burden
hours
Proposed Project: SAMHSA/CMHS
Initiative To Reduce/Eliminate
Seclusion and Restraint: 8 State
Incentive Grants and Coordinating
Center—NEW
The Substance Abuse and Mental
Health Services Administration
(SAMHSA), Center for Mental Health
Services (CMHS), has funded an
Initiative to Reduce/Eliminate Seclusion
and Restraint (S/R) which consists of 8
State Incentive Grants to Build Capacity
for Alternatives to Restraint and
Seclusion (SM04–007) and a
Coordinating Center to Support S/R
State Incentive Grants. This initiative is
designed to promote the
implementation and evaluation of best
practice approaches to reducing the use
of restraint and seclusion in mental
health facilities. Grantees consist of 8
sites (state mental health agencies), most
of which will be implementing
interventions in multiple facilities (a
total of 49 facilities). These include
E:\FR\FM\16AUN1.SGM
16AUN1
]]>Agencies
[Federal Register Volume 70, Number 157 (Tuesday, August 16, 2005)]
[Notices]
[Pages 48167-48168]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-16214]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (U.S.C. Appendix 2), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel, Protection Against Doxorubicin-Induced Cardiomyopathy.
Date: August 16, 2005.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone conference call).
Contact Person: Anshumali Chaudhari, PhD, Scientific Review
Administrator, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4124, MSC 7802, Bethesda, MD
20892, (301) 435-1210, chaudhaa@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific Review Special Emphasis
Panel, Small Business Grant Applications: Immunology.
Date: August 24, 2005.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant applications.
[[Page 48168]]
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone conference call).
Contact Person: Stephen M. Nigida, PhD, Scientific Review
Administrator, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4212, MSC 7812, Bethesda, MD
20892, 301-435-1222, nigidas@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: August 10, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-16214 Filed 8-15-05; 8:45 am]
BILLING CODE 4140-01-M
